Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT2 | P31751 | 7/20 | 0.61 |
| ▸ | AKT1 | P31749 | 4/20 | 0.61 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.60 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
| ▸ | METAP2 | P50579 | 1/20 | 0.50 |
| ▸ | METAP1 | P53582 | 1/20 | 0.50 |
| ▸ | PIM1 | P11309 | 1/20 | 0.50 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.50 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | APEX1 | P27695 | 1/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.50 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.45 |
| ▸ | PRKCG | P05129 | 1/20 | 0.45 |
| ▸ | PRKCB | P05771 | 1/20 | 0.45 |
| ▸ | BRAF | P15056 | 1/20 | 0.45 |
| ▸ | PRKCA | P17252 | 1/20 | 0.45 |
| ▸ | PRKCH | P24723 | 1/20 | 0.45 |
| ▸ | PRKCI | P41743 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15504532 | 1.00 | AKT2 (0.61) | AKT2AKT1LRRK2ROCK2KCNH2 | |
| SCHEMBL16432987 | 0.88 | AKT2 (0.76) | AKT2AKT1ROCK2PIM1PIM3 | |
| SCHEMBL15689115 | 0.88 | AKT2 (0.76) | AKT2AKT1ROCK2PIM1PIM3 | |
| SCHEMBL3717488 | 0.80 | DHODH (0.52) | AKT2AKT1LRRK2ROCK2ACVR1 | |
| SCHEMBL3740850 | 0.80 | AKT2 (0.70) | AKT2AKT1ROCK2KCNH2PIM1 | |
| SCHEMBL16131991 | 0.79 | CCR1 (0.56) | AKT2AKT1LRRK2ROCK2KCNH2 | |
| SCHEMBL13113948 | 0.79 | ROCK2 (0.54) | AKT2AKT1LRRK2ROCK2PRKD3 | |
| SCHEMBL16872766 | 0.79 | AKT2 (0.95) | AKT2AKT1ROCK2PIM1 | |
| SCHEMBL1186757 | 0.78 | AKT2 (0.57) | AKT2AKT1ROCK2ACVR1KDR | |
| SCHEMBL104535 | 0.77 | AKT2 (0.61) | AKT2AKT1ROCK2ACVR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2003051906-A2 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-06-26 | — | — | WO | claimed |
| CN-1391476-A | Vasopressin agonist formulation and process | AMERICAN CYANAMID CO (US) | 2003-01-15 | — | — | CN | claimed |
| EP-4289835-A1 | CDK INHIBITOR | Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. (CN) | 2023-12-13 | — | — | EP | disclosed |
| EP-3647311-B1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | BEIJING TIDE PHARMACEUTICAL CO LTD (CN) | 2023-11-01 | — | — | EP | disclosed |
| US-20230303534-A1 | PREPARATION METHOD FOR NOVEL RHO-RELATED PROTEIN KINASE INHIBITOR AND INTERMEDIATE IN PREPARATION METHOD | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2023-09-28 | — | — | US | disclosed |
| US-11767297-B2 | Compounds for inhibiting TNIK and medical uses thereof | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2023-09-26 | — | — | US | disclosed |
| WO-2023171305-A1 | UNSATURATED HYDROCARBON SCAVENGER, NOVEL COMPOUND, AND METAL-ORGANIC FRAMEWORK | ＥＮＥＯＳ株式会社 | 2023-09-14 | — | — | WO | disclosed |
| WO-2023069884-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | IMAGO BIOSCIENCES, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| US-11584736-B2 | Heterocyclic P2Y14 receptor antagonists | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-02-21 | — | — | US | disclosed |
| US-20230039679-A1 | COMPOUNDS FOR INHIBITING TNIK AND MEDICAL USES THEREOF | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2023-02-09 | — | — | US | disclosed |
| WO-2023280177-A1 | SMALL MOLECULE COMPOUND TARGETING BCL9/β-CATENIN INTERACTION | 南通聚太生物科技有限公司 | 2023-01-12 | — | — | WO | disclosed |
| US-20080096892-A1 | C-Kit Modulators And Methods Of Use | EXELIXIS, INC. (US) | 2008-04-24 | — | — | US | disclosed |
| WO-2008021781-A1 | TRIAZOLOTRIAZINES AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20080039457-A1 | TRIAZOLOTRIAZINES AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2008-02-14 | — | — | US | disclosed |
| US-20080039457-A1 | TRIAZOLOTRIAZINES AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2008-02-14 | — | — | US | disclosed |
| US-20070161645-A1 | Thiazole inhibitors targeting resistant kinase mutations | TARGEGEN, INC. (US) | 2007-07-12 | — | — | US | disclosed |
| US-20070149508-A1 | Six membered heteroaromatic inhibitors targeting resistant kinase mutations | TARGEGEN, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| WO-2007056023-A2 | THIAZOLE INHIBITORS TARGETING RESISTANT KINASE MUTATIONS | TARGEGEN, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007056075-A2 | SIX MEMBERED HETEROAROMATIC INHIBITORS TARGETING RESISTANT KINASE MUTATIONS | TARGEGEN, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| WO-2003051906-A2 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096892-A1 | C-Kit Modulators And Methods Of Use | KIT, PRKCH, PRKCB | AKT2 94/4885AKT1 36/4885LRRK2 1093/4885 |
| US-20080039457-A1 | TRIAZOLOTRIAZINES AS KINASE INHIBITORS | MET, ERBB2, RET | AKT2 229/4885AKT1 226/4885LRRK2 437/4885 |
| US-11584736-B2 | Heterocyclic P2Y14 receptor antagonists | P2RY14, P2RY1, P2RY13 | AKT2 1832/4885AKT1 1126/4885LRRK2 2924/4885 |
| US-20230303534-A1 | PREPARATION METHOD FOR NOVEL RHO-RELATED PROTEIN KINASE INHIBITOR AND INTERMEDIATE IN PREPARATION METHOD | ROCK1, ROCK2, ARHGDIA | AKT2 134/4885AKT1 61/4885LRRK2 565/4885 |
| US-11767297-B2 | Compounds for inhibiting TNIK and medical uses thereof | TNNI3K, TNK1, TNIK | AKT2 492/4885AKT1 609/4885LRRK2 1305/4885 |
| US-20070161645-A1 | Thiazole inhibitors targeting resistant kinase mutations | JAK2, ABL1, FLT3 | AKT2 533/4885AKT1 374/4885LRRK2 414/4885 |
| US-20070149508-A1 | Six membered heteroaromatic inhibitors targeting resistant kinase mutations | ABL1, KDR, BCR | AKT2 443/4885AKT1 191/4885LRRK2 327/4885 |
| US-20230039679-A1 | COMPOUNDS FOR INHIBITING TNIK AND MEDICAL USES THEREOF | TNNI3K, TNK1, TNIK | AKT2 492/4885AKT1 609/4885LRRK2 1305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.